Thrombin-like enzyme that shows clotting activity upon human plasma. Shows specific fibrinogenolytic activity for Aalpha chain (FGA). Hydrolyzes fibrin, BAPNA and TAME, as well as chromogenic artificial substrates of the blood coagulation cascasde: S-27654 for factor X (F10), S-2302 for kallikrein (KLK), factor XIa (F11), and XIIa (F12), and S-2266 for kallikrein and factor XIa (F11). Subcutaneous injection into mice induces a mild edema. Intravenous and intramuscular injection reduce plasma fibrinogen concentration and increase the levels of fibrin(ogen) degradation products. Intramuscular injection also promotes an increase in the expression of proMMP-9, but is unable to activate it. Inhibited by leupeptin, heparin, and 1.10-phenantroline. Monomer. Expressed by the venom gland. N-glycosylated. Contains sialic acid residues. Deglycosylation reduces in 50% the formation of fibrin clot. Does not show hemorrhagic and myotoxic activities (PubMed:17466550), as well as activity on platelet aggregation and plasmin (represented by the chromogenic substrate S-2251) (PubMed:17996740). Belongs to the peptidase S1 family. Snake venom subfamily.